Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

NFlection presents positive phase IIa data for NFX-179 gel

May 27, 2021

Connect begins phase I trial of CBP-174 for chronic inflammatory pruritus

May 26, 2021

Sonelokimab shows significant clinical benefit over placebo in patients with plaque psoriasis

May 26, 2021

Incyte initiates phase II study of INCB-054707 in nonsegmental vitiligo

May 21, 2021

First patients dosed in phase I study of PBI-100

May 21, 2021

Olix initiates phase II study of OLX-10010 as treatment of hypertrophic scars

May 21, 2021

China's NMPA approves phase I trial of InnoCare's TYK2 inhibitor ICP-332

May 19, 2021

Phase III trials of ruxolitinib in vitiligo meet endpoints

May 17, 2021

Dosing begins in phase II trial of CGB-400 for rosacea

May 14, 2021

Reistone begins phase III trial of oral SHR-0302 in moderate to severe atopic dermatitis

May 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...